These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 3486945)

  • 1. Monoamine oxidase B, smoking, and Parkinson's disease.
    Yong VW; Perry TL
    J Neurol Sci; 1986 Feb; 72(2-3):265-72. PubMed ID: 3486945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of tobacco smoke constituents on MPTP-induced toxicity and monoamine oxidase activity in the mouse brain.
    Carr LA; Basham JK
    Life Sci; 1991; 48(12):1173-7. PubMed ID: 2002748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role for monoamine oxidase-A (MAO-A) in the bioactivation and nigrostriatal dopaminergic neurotoxicity of the MPTP analog, 2'Me-MPTP.
    Kindt MV; Youngster SK; Sonsalla PK; Duvoisin RC; Heikkila RE
    Eur J Pharmacol; 1988 Feb; 146(2-3):313-8. PubMed ID: 3131149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism of the neurotoxin in MPTP by human liver monoamine oxidase B.
    Fritz RR; Abell CW; Patel NT; Gessner W; Brossi A
    FEBS Lett; 1985 Jul; 186(2):224-8. PubMed ID: 3874094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of MAO in MPTP toxicity--a review.
    Glover V; Gibb C; Sandler M
    J Neural Transm Suppl; 1986; 20():65-76. PubMed ID: 3091762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the biological activity of several analogs of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Youngster SK; Sonsalla PK; Heikkila RE
    J Neurochem; 1987 Mar; 48(3):929-34. PubMed ID: 3492590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Difference in monoamine oxidase B activity between C57 black and albino NMRI mouse strains may explain differential effects of the neurotoxin MPTP.
    Zimmer J; Geneser FA
    Neurosci Lett; 1987 Aug; 78(3):253-8. PubMed ID: 3498133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of monoamine oxidase enzymes in the action of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, a selective neurotoxin, in the squirrel monkey: binding and biochemical studies.
    Del Zompo M; Piccardi MP; Bernardi F; Bonuccelli U; Corsini GU
    Brain Res; 1986 Jul; 378(2):320-4. PubMed ID: 3089539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunity of fetal mice to prenatal administration of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Melamed E; Rosenthal J; Youdim MB
    J Neurochem; 1990 Oct; 55(4):1427-31. PubMed ID: 2398363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tobacco leaf, smoke and smoking, MAO inhibitors, Parkinson's disease and neuroprotection; are there links?
    Castagnoli K; Murugesan T
    Neurotoxicology; 2004 Jan; 25(1-2):279-91. PubMed ID: 14697903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet monoamine oxidase B activity in parkinsonian patients.
    Bonuccelli U; Piccini P; Del Dotto P; Pacifici GM; Corsini GU; Muratorio A
    J Neurol Neurosurg Psychiatry; 1990 Oct; 53(10):854-5. PubMed ID: 2266365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selegiline and the prophylaxis of Parkinson's disease.
    Sandler M; Willoughby J; Glover V; Gibb C
    J Neural Transm Suppl; 1987; 25():35-43. PubMed ID: 3123604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Participation of brain monoamine oxidase B form in the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: relationship between the enzyme inhibition and the neurotoxicity.
    Kinemuchi H; Arai Y; Toyoshima Y
    Neurosci Lett; 1985 Jul; 58(2):195-200. PubMed ID: 3876524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the oxidation of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase B.
    Heikkila RE; Manzino L; Cabbat FS; Duvoisin RC
    J Neurochem; 1985 Oct; 45(4):1049-54. PubMed ID: 3928814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: partial protection against striato-nigral dopamine depletion in C57BL/6J mice by cigarette smoke exposure and by beta-naphthoflavone-pretreatment.
    Shahi GS; Das NP; Moochhala SM
    Neurosci Lett; 1991 Jun; 127(2):247-50. PubMed ID: 1881637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The interactions of monoamine oxidase with some derivatives of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Sullivan JP; Tipton KF
    J Neural Transm Suppl; 1990; 29():269-77. PubMed ID: 2358804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine with monoamine oxidases.
    Singer TP; Salach JI; Castagnoli N; Trevor A
    Biochem J; 1986 May; 235(3):785-9. PubMed ID: 3489461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation and characterization of a monoamine oxidase B selective inhibitor from tobacco smoke.
    Khalil AA; Davies B; Castagnoli N
    Bioorg Med Chem; 2006 May; 14(10):3392-8. PubMed ID: 16458520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropharmacological actions of cigarette smoke: brain monoamine oxidase B (MAO B) inhibition.
    Fowler JS; Volkow ND; Wang GJ; Pappas N; Logan J; MacGregor R; Alexoff D; Wolf AP; Warner D; Cilento R; Zezulkova I
    J Addict Dis; 1998; 17(1):23-34. PubMed ID: 9549600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of fluorinated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs with potent nigrostriatal toxicity for potential use in positron emission tomography studies.
    Harik SI; Riachi NJ; Hritz MA; Berridge MS; Sayre LM
    J Pharmacol Exp Ther; 1993 Aug; 266(2):790-5. PubMed ID: 8355208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.